Press releases

Copenhagen, Denmark, 26 February 2026 - Curasight A/S (TICKER: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand therapy platform  across multiple aggressive solid tumors, hereby publishes the Annual Report 2025. The report is available as an attached file to this release and on the Company's website. Below is a summary of the report.

Copenhagen, Denmark, 26 February 2026 - Curasight A/S (TICKER: CURAS), a clinical-stage radiopharmaceutical company pioneering a first-in-class uPAR-targeted radioligand therapy platform  addressing multiple aggressive solid tumors, hereby publishes the Year-end report Q4 2025. The Year-end report is available as an attached file to this release and on the Company's website. Below is a summary of the report.

COPENHAGEN, Denmark, February 17, 2026 - Curasight A/S (TICKER:CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand platform therapies across multiple aggressive solid tumors, will present recent company progress including the ongoing Phase 1 clinical trial uTREAT® in glioblastoma, at the TD Cowen 46[th] Annual Health Care Conference on Tuesday, March 3[rd], 2026, at 11:50 a.m. Eastern Time / 5:50 p.m. CET in Boston.

Copenhagen, 9 February 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) announces that the company has received notification that Pentwater Capital Management LP, 1001 10th Avenue South, Naples, FL 34102, on 3. February 2026 has reduced its holding of shares in the Company.

· Clear uptake of uTREAT® in aggressive brain cancer (glioblastoma)
· Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and more targeted treatment of high-grade gliomas and other uPAR expressing aggressive solid tumors
 

Copenhagen, 12[th] January, 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen activator receptor), the functional driver of invasion, angiogenesis, and metastasis across most solid tumors, today announced encouraging preliminary data from the first patient dosed in ongoing Phase 1 clinical trial in patients with high-grade gliomas.

Copenhagen, 5 January 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) a clinical-stage theranostic company focused on diagnosing and treating certain types of cancers, announced that CEO Ulrich Krasilnikoff and CMO prof. Andreas Kjær will be in San Francisco during the 44[th] J.P. Morgan Healthcare Conference being held January 12-15, 2026.